Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Medically reviewed by Lindsay Cook, PharmD Type 2 diabetes is a form of diabetes characterized by high blood sugar (glucose), ...

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

Expert Rev Endocrinol Metab. 2008;3(6):691-697. Elimination of sitagliptin occurs primarily via renal excretion (79%) and involves active tubular secretion. Sitagliptin is a substrate for human ...